RBC Affirms Biogen (BIIB) at 'Outperform'; Roche's RRMS, PPMS Data Expected, But More Details Needed
-
Human Genome (HGSI) Could Become Takeover Target Upon Approval of Benlysta
-
RBC Capital Downgrades Immunogen (IMGN) to Sector Perform

